Table 4 Outliers identified by Deming regression analysis
Patient age, gender, and clinical history | Serum | EDTA-plasma | Lithium heparin PST | ||||||
|---|---|---|---|---|---|---|---|---|---|
Kappa (mg/L) | Lambda (mg/L) | K/L | Kappa (mg/L) | Lambda (mg/L) | K/L | Kappa (mg/L) | Lambda (mg/L) | K/L | |
Kappa outliers | |||||||||
60 Y M, multiple myeloma, kappa light chain | 46.1 | 14.7 | 3.14 | 107 | 15.0 | 7.16 | 55.8 | 14.7 | 3.80 |
59 Y F, multiple myeloma, IgG kappa | 6684 | 6.1 | 1096 | 7764 | 6.1 | 1273 | 7125 | 6.7 | 1063 |
52 Y M, multiple myeloma, IgG kappa | 337 | 11.0 | 30.6 | 419 | 11.1 | 37.8 | 415 | 11.2 | 37.1 |
60 Y M, multiple myeloma, IgG kappa | 56.2 | 10.5 | 5.35 | 112 | 10.3 | 10.87 | 91.9 | 10.8 | 8.51 |
59 Y M, multiple myeloma, IgG kappa | 128 | 6.1 | 21.03 | 177 | 7.2 | 24.6 | 197 | 6.2 | 31.8 |
Lambda outliers | |||||||||
60 Y M, plasma cell leukemia, IgG lambda | 4.0 | 693 | 0.01 | 5.7 | 672 | 0.01 | 5.0 | 621 | 0.01 |
74 Y F, multiple myeloma, IgG lambda | 4.4 | 1590 | 0.00 | 6.7 | 1457 | 0.00 | 5.2 | 1571 | 0.00 |
55 Y F, multiple myeloma, lambda light chain | 11.8 | 1334 | 0.01 | 12.7 | 1747 | 0.01 | 12.0 | 1562 | 0.01 |
65 Y M, multiple myeloma, lambda light chain | 9.9 | 278 | 0.04 | 12.5 | 311 | 0.04 | 10.1 | 278 | 0.04 |
59 Y F, acute renal failure, seropositive rheumatoid arthritis | 29.8 | 36.4 | 0.82 | 28.8 | 27.2 | 1.06 | 25.9 | 27.4 | 0.95 |
62 Y M, biclonal IgG kappa + lambda light chain | 3.1 | 1195 | <0.01 | 4.7 | 1275 | <0.01 | 3.4 | 1103 | <0.01 |
66 Y F, multiple myeloma, lambda light chain | 17.0 | 296 | 0.06 | 19.7 | 263 | 0.08 | 19.3 | 359 | 0.05 |